J. Scott Hassell, M.D., Plano Urologist
, closely watches new drug used to help Men with Hard-To-Treat Prostate Cancer.
According to new findings, abiraterone acetate, an investigational drug, can prolong survival of men with metastatic castration-resistant prostate cancer (CRPC) whose disease is progressing after receiving docetaxel-based chemotherapy.
Lead researcher Howard Scher, M.D., of Memorial Sloan Kettering Cancer Center (MSKCC) in New York, reported at the 4th annual Genitourinary Cancers Symposium that abiraterone acetate prolonged survival by a median of approximately 4 months. Abiraterone acetate recipients had a 35% decreased risk of death relative to those in the placebo group.
Dr. Howard Scher, Chief of Genitourinary Oncology Service at MSKCC's Sidney Kimmel Center for Urologic & Prostate Cancers, & his collaborators also observed improvements in secondary end points attributable to abiraterone acetate, such as time to PSA progression, radiographic progression-free survival & PSA response rate. Notable as well, was that the safety profile (adverse events or toxicities observed in patients receiving abiraterone acetate) was very similar to the placebo treated patients, Dr. Scher said. The events that occurred more frequently in abiraterone acetate treated patients were fluid retention, hypertension & hypokalemia which are related to the known mechanism of action of the drug respectively.
"These results establish that considering CRPC to be ‘hormone refractory' may deny patients a safe and life-prolonging treatment," Dr. Howard Scher told attendees.
Johnson & Johnson funded the study, their Company is responsible for developing the new drug.







